Next |
home / stock / hcm / hcm message board
Subject | By | Source | When |
---|---|---|---|
The now last up | MWM | investorshub | 05/10/2023 3:35:25 PM |
$HCM Time for this to show some returns | MWM | investorshub | 05/08/2023 7:41:07 PM |
$HCM MomentumIts gaining | crowin | investorshub | 05/08/2023 7:12:07 AM |
short squeeze | MWM | investorshub | 05/08/2023 1:11:22 AM |
$HCM The trading last up | MWM | investorshub | 05/07/2023 6:33:31 AM |
$HCM short squeeze article | whytestocks | investorshub | 05/06/2023 9:53:34 PM |
Price trading | MWM | investorshub | 05/05/2023 9:18:06 PM |
$HCM Long and strong lets hope im right | MWM | investorshub | 05/05/2023 4:48:34 PM |
$HCM MomentumIts gaining | MWM | investorshub | 05/05/2023 4:02:32 AM |
The gaining last trade up | whytestocks | investorshub | 05/03/2023 9:45:33 AM |
$HCM Price now last up | MWM | investorshub | 05/02/2023 10:45:25 PM |
Anyone hear anything lately? Want to see this one go | MWM | investorshub | 05/02/2023 11:20:59 AM |
$HCM The gaining last trade up | MWM | investorshub | 04/29/2023 9:17:57 AM |
$HCM MomentumIts now | MWM | investorshub | 04/27/2023 11:38:50 AM |
short squeeze article | hang ten | investorshub | 04/26/2023 11:58:21 AM |
$HCM we got news | crowin | investorshub | 04/24/2023 8:21:44 PM |
$HCM here we go bulls news is here | Stock | investorshub | 04/24/2023 1:25:02 PM |
$HCM What do you make of this? | hang ten | investorshub | 04/22/2023 6:56:12 PM |
Do we have a winner?Turn around time? | Stock | investorshub | 04/22/2023 11:32:05 AM |
Anyone hear anything lately? Want to see this one go | MWM | investorshub | 04/20/2023 10:56:15 AM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
4.59%Change Percent:
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) tod...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data rela...
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui...